Engineered immune cells take on liver cancer in early trial

NCT ID NCT07039201

Recruiting now Disease control Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests a new treatment called CG-102-12C for people with advanced liver cancer that has not responded to standard treatments. The therapy uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The trial will enroll 12 participants to check if the treatment is safe and to see if it can shrink tumors or control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CG-102-12C (a type of CAR T-cell therapy made from the patient's own immune cells)
What this could lead to: If it works, this could point toward a new treatment option for advanced liver cancer that has stopped responding to standard therapies.
What could go wrong: This is a very early, small study (only 12 people) focused mainly on safety. The treatment may not shrink tumors, and there are risks of serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

First Affiliated Hospital, Medical College of Zhejiang University
NOT_YET_RECRUITING

Hangzhou, Zhejiang, 310003, China
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.